{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:22:00Z","timestamp":1791505320984,"version":"4.3.4"},"reference-count":128,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T00:00:00Z","timestamp":1665705600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Allergology International"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.alit.2022.09.005","type":"journal-article","created":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T08:51:50Z","timestamp":1667292710000},"page":"234-244","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Biologics for allergy: therapeutic potential for ocular allergic diseases and adverse effects on the eye"],"prefix":"10.1016","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4990-6308","authenticated-orcid":false,"given":"Ken","family":"Fukuda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuma","family":"Kishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamaki","family":"Sumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Yamashiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Ebihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.alit.2022.09.005_bib1","first-page":"3599","article-title":"Biotherapies in uveitis","volume":"9","author":"Leclercq","year":"2020","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.alit.2022.09.005_bib2","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(18)31550-2","article-title":"Age-related macular degeneration","volume":"392","author":"Mitchell","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.alit.2022.09.005_bib3","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/all.14027","article-title":"New biological treatments for asthma and skin allergies","volume":"75","author":"Eyerich","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2022.09.005_bib4","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.alit.2020.03.002","article-title":"The start of a new era of biologics for treating allergic diseases","volume":"69","author":"Izuhara","year":"2020","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2022.09.005_bib5","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.alit.2022.07.005","article-title":"Executive summary: Japanese Guidelines for allergic conjunctival diseases 2021","volume":"71","author":"Miyazaki","year":"2022","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2022.09.005_bib6","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.alit.2020.03.005","article-title":"Japanese guidelines for allergic conjunctival diseases 2020","volume":"69","author":"Miyazaki","year":"2020","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2022.09.005_bib7","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2332\/allergolint.54.51","article-title":"Treatment of corneal lesions in individuals with vernal keratoconjunctivitis","volume":"54","author":"Kumagai","year":"2005","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2022.09.005_bib8","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.preteyeres.2005.09.002","article-title":"Role of structural cells of the cornea and conjunctiva in the pathogenesis of vernal keratoconjunctivitis","volume":"25","author":"Kumagai","year":"2006","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.alit.2022.09.005_bib9","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1350-9462(02)00006-X","article-title":"Vernal keratoconjunctivitis: pathogenesis and treatment","volume":"21","author":"Leonardi","year":"2002","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.alit.2022.09.005_bib10","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ophtha.2015.07.012","article-title":"Atopic keratoconjunctivitis in children: clinical features and diagnosis","volume":"123","author":"Bremond-Gignac","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.alit.2022.09.005_bib11","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/ACI.0b013e32833e16e4","article-title":"Atopic keratoconjunctivitis and atopic dermatitis","volume":"10","author":"Guglielmetti","year":"2010","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2022.09.005_bib12","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/ICU.0000000000000532","article-title":"Ocular involvement in atopic disease: a review","volume":"29","author":"Patel","year":"2018","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.alit.2022.09.005_bib13","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S0161-6420(91)32322-4","article-title":"Clinical features of atopic keratoconjunctivitis","volume":"98","author":"Tuft","year":"1991","journal-title":"Ophthalmology"},{"key":"10.1016\/j.alit.2022.09.005_bib14","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jaci.2009.06.012","article-title":"Critical role of IgE-dependent mast cell activation in a murine model of allergic conjunctivitis","volume":"124","author":"Fukuda","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2022.09.005_bib15","first-page":"296","article-title":"IgE and non-IgE mechanisms in ocular allergy","volume":"71","author":"Bonini","year":"1993","journal-title":"Ann Allergy"},{"key":"10.1016\/j.alit.2022.09.005_bib16","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0161-6420(00)00092-0","article-title":"Vernal keratoconjunctivitis revisited: a case series of 195 patients with long-term followup","volume":"107","author":"Bonini","year":"2000","journal-title":"Ophthalmology"},{"key":"10.1016\/j.alit.2022.09.005_bib17","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1046\/j.1365-2745.2003.01616.x","article-title":"Vernal keratoconjunctivitis: evidence for immunoglobulin E-dependent and immunoglobulin E-independent eosinophilia","volume":"33","author":"Ono","year":"2003","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.alit.2022.09.005_bib18","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1007\/s10792-019-01101-z","article-title":"Local allergic conjunctivitis: a phenotype of allergic conjunctivitis","volume":"39","author":"Yamana","year":"2019","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.alit.2022.09.005_bib19","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/ACI.0b013e3282ef8674","article-title":"Immunopathogenesis of ocular allergy: a schematic approach to different clinical entities","volume":"7","author":"Leonardi","year":"2007","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2022.09.005_bib20","doi-asserted-by":"crossref","first-page":"5194","DOI":"10.1167\/iovs.15-16563","article-title":"Roles of epithelial cell-derived type 2-initiating cytokines in experimental allergic conjunctivitis","volume":"56","author":"Asada","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"Suppl 1","key":"10.1016\/j.alit.2022.09.005_bib21","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1097\/ICO.0b013e3181ea9958","article-title":"The epithelium takes center stage in allergic keratoconjunctivitis","volume":"29","author":"Ebihara","year":"2010","journal-title":"Cornea"},{"key":"10.1016\/j.alit.2022.09.005_bib22","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.3390\/cells11061051","article-title":"Role of damage-associated molecular patterns (DAMPs\/Alarmins) in severe ocular allergic diseases","volume":"11","author":"Fukuda","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.alit.2022.09.005_bib23","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s10384-017-0528-7","article-title":"Cytokine expression and barrier disruption in human corneal epithelial cells induced by alarmin released from necrotic cells","volume":"61","author":"Fukuda","year":"2017","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.alit.2022.09.005_bib24","doi-asserted-by":"crossref","first-page":"5817","DOI":"10.1167\/iovs.13-11969","article-title":"Alarmins from corneal epithelial cells upregulate CCL11 and VCAM-1 in corneal fibroblasts","volume":"54","author":"Fukuda","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.alit.2022.09.005_bib25","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1167\/iovs.09-4183","article-title":"Functional role of thymic stromal lymphopoietin in chronic allergic keratoconjunctivitis","volume":"51","author":"Matsuda","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.alit.2022.09.005_bib26","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/978-1-0716-1001-5_10","article-title":"Experimental mouse models of ragweed- and papain-induced allergic conjunctivitis","volume":"2223","author":"Matsuda","year":"2021","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.alit.2022.09.005_bib27","doi-asserted-by":"crossref","first-page":"4646","DOI":"10.1167\/iovs.08-3365","article-title":"The role of interleukin-33 in chronic allergic conjunctivitis","volume":"50","author":"Matsuda","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.alit.2022.09.005_bib28","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/iid3.189","article-title":"Contributions of Interleukin-33 and TSLP in a papain-soaked contact lens-induced mouse conjunctival inflammation model","volume":"5","author":"Sugita","year":"2017","journal-title":"Immun Inflamm Dis"},{"key":"10.1016\/j.alit.2022.09.005_bib29","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1167\/iovs.09-4122","article-title":"TSLP and downstream molecules in experimental mouse allergic conjunctivitis","volume":"51","author":"Zheng","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.alit.2022.09.005_bib30","first-page":"5072781","article-title":"Expression of TSLP and downstream molecules IL-4, IL-5, and IL-13 on the eye surface of patients with various types of allergic conjunctivitis","volume":"2016","author":"Zheng","year":"2016","journal-title":"J\u00a0Ophthalmol"},{"key":"10.1016\/j.alit.2022.09.005_bib31","doi-asserted-by":"crossref","first-page":"108229","DOI":"10.1016\/j.exer.2020.108229","article-title":"Corneal fibroblasts: function and markers","volume":"200","author":"Fukuda","year":"2020","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.alit.2022.09.005_bib32","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/00003226-200308000-00014","article-title":"Synergistic effect of TNF-\u03b1 and either IL-4 or IL-13 on VCAM-1 expression by cultured human corneal fibroblasts","volume":"22","author":"Kumagai","year":"2003","journal-title":"Cornea"},{"issue":"Suppl 1","key":"10.1016\/j.alit.2022.09.005_bib33","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1097\/ICO.0000000000002548","article-title":"Roles of type 2 immune response-initiating cytokines and detection of type 2 innate lymphoid cells in mouse models of allergic conjunctivitis","volume":"39","author":"Asada","year":"2020","journal-title":"Cornea"},{"key":"10.1016\/j.alit.2022.09.005_bib34","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.iac.2010.06.004","article-title":"Atopic dermatitis and keratoconjunctivitis","volume":"30","author":"Bielory","year":"2010","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.alit.2022.09.005_bib35","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1046\/j.1365-2222.1999.00585.x","article-title":"Cytokine production and mRNA expression by conjunctival T-cell lines in chronic allergic eye disease","volume":"29","author":"Calder","year":"1999","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.alit.2022.09.005_bib36","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1007\/s00417-006-0285-7","article-title":"Th1- and Th2-type cytokines in chronic ocular allergy","volume":"244","author":"Leonardi","year":"2006","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.alit.2022.09.005_bib37","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/01.all.0000182547.60595.64","article-title":"The Th1\/Th2 paradigm in ocular allergy","volume":"5","author":"Stern","year":"2005","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2022.09.005_bib38","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0091-6749(97)70279-3","article-title":"T-cell cytokines in chronic allergic eye disease","volume":"100","author":"Metz","year":"1997","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2022.09.005_bib39","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.anai.2019.11.014","article-title":"ICON: diagnosis and management of allergic conjunctivitis","volume":"124","author":"Bielory","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.alit.2022.09.005_bib40","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jaci.2004.10.042","article-title":"Allergic conjunctivitis: update on pathophysiology and prospects for future treatment","volume":"115","author":"Ono","year":"2005","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2022.09.005_bib41","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/j.1365-2222.2011.03835.x","article-title":"Sublingual immunotherapy for allergic conjunctivitis: Cochrane systematic review and meta-analysis","volume":"41","author":"Calderon","year":"2011","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.alit.2022.09.005_bib42","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ophtha.2016.11.002","article-title":"Steroid-sparing effect of 0.1% tacrolimus eye drop for treatment of shield ulcer and corneal epitheliopathy in refractory allergic ocular diseases","volume":"124","author":"Miyazaki","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.alit.2022.09.005_bib43","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1136\/bjophthalmol-2013-304453","article-title":"Therapeutic effects of 0.1% tacrolimus eye drops for refractory allergic ocular diseases with proliferative lesion or corneal involvement","volume":"98","author":"Fukushima","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.alit.2022.09.005_bib44","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1089\/jop.2009.0087","article-title":"A\u00a0randomized, placebo-controlled clinical trial of tacrolimus ophthalmic suspension 0.1% in severe allergic conjunctivitis","volume":"26","author":"Ohashi","year":"2010","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"key":"10.1016\/j.alit.2022.09.005_bib45","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1089\/jop.2008.0103","article-title":"A\u00a0large prospective observational study of novel cyclosporine 0.1% aqueous ophthalmic solution in the treatment of severe allergic conjunctivitis","volume":"25","author":"Ebihara","year":"2009","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"key":"10.1016\/j.alit.2022.09.005_bib46","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1016\/S0161-6420(97)30052-9","article-title":"Ocular-hypertensive response to topical steroids in children","volume":"104","author":"Kwok","year":"1997","journal-title":"Ophthalmology"},{"key":"10.1016\/j.alit.2022.09.005_bib47","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/bjo.81.5.421d","article-title":"Accelerated ocular hypertensive response to topical steroids in children","volume":"81","author":"Lam","year":"1997","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.alit.2022.09.005_bib48","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ophtha.2018.12.027","article-title":"A\u00a0randomized, controlled trial of cyclosporine A cationic emulsion in pediatric vernal keratoconjunctivitis: the VEKTIS study","volume":"126","author":"Leonardi","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.alit.2022.09.005_bib49","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s10384-020-00774-9","article-title":"Reduced steroid-induced intraocular pressure elevation in tacrolimus-treated refractory allergic ocular diseases","volume":"64","author":"Miyazaki","year":"2020","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.alit.2022.09.005_bib50","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.alit.2020.01.004","article-title":"Roles of omalizumab in various allergic diseases","volume":"69","author":"Okayama","year":"2020","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2022.09.005_bib51","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1111\/bcp.13338","article-title":"Ocular myasthenic syndrome, adverse reaction to omalizumab? A case report","volume":"83","author":"Kalteren","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.alit.2022.09.005_bib52","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2332\/allergolint.55.379","article-title":"Omalizumab is effective and safe in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis","volume":"55","author":"Okubo","year":"2006","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2022.09.005_bib53","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1016\/j.jaip.2020.04.068","article-title":"Add-on omalizumab for inadequately controlled severe pollinosis despite standard-of-care: a randomized study","volume":"8","author":"Okubo","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2022.09.005_bib54","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1365-2222.2007.02894.x","article-title":"Omalizumab is more effective than suplatast tosilate in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis","volume":"38","author":"Nagakura","year":"2008","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.alit.2022.09.005_bib55","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1111\/j.1398-9995.2004.00552.x","article-title":"The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children","volume":"59","author":"Rolinck-Werninghaus","year":"2004","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2022.09.005_bib56","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/ced.15000","article-title":"Successful treatment of severe recalcitrant vernal keratoconjunctivitis and atopic dermatitis associated with elevated IgE levels with omalizumab","volume":"47","author":"Zengarini","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.alit.2022.09.005_bib57","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/iid3.384","article-title":"Clinical efficacy and safety of omalizumab in conventional treatment-resistant vernal keratoconjunctivitis: our experience and literature review","volume":"9","author":"Manti","year":"2021","journal-title":"Immun Inflamm Dis"},{"key":"10.1016\/j.alit.2022.09.005_bib58","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.anai.2018.09.458","article-title":"Omalizumab as single-dose therapy for vernal keratoconjunctivitis","volume":"122","author":"Simpson","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.alit.2022.09.005_bib59","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/pai.12737","article-title":"Vernal keratoconjunctivitis treated with omalizumab: a case series","volume":"28","author":"Occasi","year":"2017","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.alit.2022.09.005_bib60","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40123-016-0074-2","article-title":"Omalizumab in severe refractory vernal keratoconjunctivitis in children: case series and review of the literature","volume":"6","author":"Doan","year":"2017","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.alit.2022.09.005_bib61","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1001\/jamaophthalmol.2015.5679","article-title":"Omalizumab treatment of vernal keratoconjunctivitis","volume":"134","author":"Heffler","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.alit.2022.09.005_bib62","first-page":"305","article-title":"Severe vernal keratoconjunctivitis successfully treated with subcutaneous omalizumab","volume":"17","author":"de Klerk","year":"2013","journal-title":"J\u00a0AAPOS"},{"key":"10.1016\/j.alit.2022.09.005_bib63","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.aller.2011.08.002","article-title":"Omalizumab. An option in vernal keratoconjunctivitis?","volume":"40","author":"Sanchez","year":"2012","journal-title":"Allergol Immunopathol (Madr)"},{"key":"10.1016\/j.alit.2022.09.005_bib64","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/pai.12350","article-title":"Vernal Keratoconjunctivitis and immune-mediated diseases: one unique way to symptom control?","volume":"26","author":"Occasi","year":"2015","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.alit.2022.09.005_bib65","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1159\/000508031","article-title":"Vernal keratoconjunctivitis: a case of anti-IgE treatment with short-lasting remission","volume":"11","author":"Gatta","year":"2020","journal-title":"Case Rep Ophthalmol"},{"key":"10.1016\/j.alit.2022.09.005_bib66","doi-asserted-by":"crossref","DOI":"10.1136\/bcr.04.2010.2919","article-title":"Omalizumab for severe atopic keratoconjunctivitis","volume":"2010","author":"Taille","year":"2010","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.alit.2022.09.005_bib67","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1517\/14712598.5.12.1603","article-title":"Omalizumab: a future innovation for treatment of severe ocular allergy?","volume":"5","author":"Williams","year":"2005","journal-title":"Expet Opin Biol Ther"},{"key":"10.1016\/j.alit.2022.09.005_bib68","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2332\/allergolint.55.121","article-title":"Fibroblasts as local immune modulators in ocular allergic disease","volume":"55","author":"Fukuda","year":"2006","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2022.09.005_bib69","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0014-4835(02)00248-8","article-title":"IL-4-induced cell proliferation and production of extracellular matrix proteins in human conjunctival fibroblasts","volume":"76","author":"Fujitsu","year":"2003","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.alit.2022.09.005_bib70","first-page":"183","article-title":"Characterization of the interleukin-4 receptor complex in human corneal fibroblasts","volume":"43","author":"Fukuda","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.alit.2022.09.005_bib71","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1136\/bjo.2009.173419","article-title":"Expression of the interleukin-4 receptor alpha in human conjunctival epithelial cells","volume":"94","author":"Ueta","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.alit.2022.09.005_bib72","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s10384-011-0030-6","article-title":"Expression of interleukin-4 receptor alpha in human corneal epithelial cells","volume":"55","author":"Ueta","year":"2011","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.alit.2022.09.005_bib73","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.alit.2020.01.002","article-title":"Dupilumab: basic aspects and applications to allergic diseases","volume":"69","author":"Matsunaga","year":"2020","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2022.09.005_bib74","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.anai.2022.05.031","article-title":"Atopic keratoconjunctivitis alleviated with dupilumab","volume":"129","author":"Chen","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.alit.2022.09.005_bib75","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.jaip.2019.10.011","article-title":"Amelioration of conjunctival giant papillae by dupilumab in patients with atopic keratoconjunctivitis","volume":"8","author":"Fukuda","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2022.09.005_bib76","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1111\/ceo.14142","article-title":"Successful treatment and prevention of the recurrence of refractory vernal keratoconjunctivitis with dupilumab","volume":"50","author":"Tsui","year":"2022","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.alit.2022.09.005_bib77","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/bjd.17869","article-title":"Conjunctivitis in dupilumab clinical trials","volume":"181","author":"Akinlade","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.alit.2022.09.005_bib78","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s40257-020-00577-1","article-title":"Conjunctivitis in dupilumab clinical trials for adolescents with atopic dermatitis or asthma","volume":"22","author":"Bansal","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.alit.2022.09.005_bib79","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaad.2020.08.051","article-title":"Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis","volume":"84","author":"Halling","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.alit.2022.09.005_bib80","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.jaad.2020.11.042","article-title":"Retrospective analysis of adverse events with dupilumab reported to the United States Food and Drug Administration","volume":"84","author":"Wang","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.alit.2022.09.005_bib81","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.alit.2018.12.012","article-title":"Development of conjunctivitis with a conjunctival proliferative lesion in a patient treated with dupilumab for atopic dermatitis","volume":"68","author":"Fukuda","year":"2019","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2022.09.005_bib82","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1080\/09546634.2019.1711010","article-title":"Punctal stenosis associated with dupilumab therapy for atopic dermatitis","volume":"32","author":"Lee","year":"2021","journal-title":"J\u00a0Dermatol Treat"},{"key":"10.1016\/j.alit.2022.09.005_bib83","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1001\/jamadermatol.2018.3427","article-title":"Cicatrizing blepharoconjunctivitis occurring during dupilumab treatment and a proposed algorithm for its management","volume":"154","author":"Levine","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.alit.2022.09.005_bib84","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1097\/ICO.0000000000002262","article-title":"Dupilumab-associated conjunctivitis in patients with atopic dermatitis","volume":"39","author":"Liberman","year":"2020","journal-title":"Cornea"},{"key":"10.1016\/j.alit.2022.09.005_bib85","first-page":"303","article-title":"Dupilumab-associated blepharoconjunctivitis with giant papillae","volume":"13","author":"Vingopoulos","year":"2020","journal-title":"Int Med Case Rep J"},{"key":"10.1016\/j.alit.2022.09.005_bib86","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s40268-019-00288-x","article-title":"A\u00a0clinician's guide to the recognition and management of dupilumab-associated conjunctivitis","volume":"19","author":"Agnihotri","year":"2019","journal-title":"Drugs R D"},{"key":"10.1016\/j.alit.2022.09.005_bib87","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1016\/j.jaip.2018.01.034","article-title":"Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab-clinical characteristics and treatment","volume":"6","author":"Wollenberg","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2022.09.005_bib88","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s40123-019-0191-9","article-title":"Ocular surface diseases induced by dupilumab in severe atopic dermatitis","volume":"8","author":"Maudinet","year":"2019","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.alit.2022.09.005_bib89","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/ijd.14573","article-title":"Real-world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients' records","volume":"59","author":"Wang","year":"2020","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.alit.2022.09.005_bib90","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.alit.2022.09.005_bib91","doi-asserted-by":"crossref","first-page":"100848","DOI":"10.1016\/j.ajoc.2020.100848","article-title":"Corneal ulceration associated with dupilumab use in a patient with atopic dermatitis","volume":"19","author":"Li","year":"2020","journal-title":"Am J Ophthalmol Case Rep"},{"key":"10.1016\/j.alit.2022.09.005_bib92","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1097\/ICO.0000000000002854","article-title":"Corneal perforation in patients under treatment with dupilumab for atopic dermatitis","volume":"41","author":"Phylactou","year":"2022","journal-title":"Cornea"},{"key":"10.1016\/j.alit.2022.09.005_bib93","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/jdv.16724","article-title":"Incidence and risk factors for dupilumab associated ocular adverse events: a real-life prospective study","volume":"35","author":"Touhouche","year":"2021","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.alit.2022.09.005_bib94","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.1167\/iovs.14-15496","article-title":"IL-13 stimulates proliferation and expression of mucin and immunomodulatory genes in cultured conjunctival goblet cells","volume":"56","author":"Tukler Henriksson","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.alit.2022.09.005_bib95","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1111\/all.15326","article-title":"IL-4 and IL-13 both contribute to the homeostasis of human conjunctival goblet cells in\u00a0vitro","volume":"77","author":"Hansen","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2022.09.005_bib96","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1111\/bjd.17538","article-title":"Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis","volume":"180","author":"Bakker","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.alit.2022.09.005_bib97","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1167\/tvst.9.3.29","article-title":"Dupilumab-associated mucin deficiency (DAMD)","volume":"9","author":"Barnett","year":"2020","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.alit.2022.09.005_bib98","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1111\/jdv.15914","article-title":"Recurrence of conjunctival goblet cells after discontinuation of dupilumab in a patient with dupilumab-related conjunctivitis","volume":"34","author":"Voorberg","year":"2020","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.alit.2022.09.005_bib99","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1111\/all.15064","article-title":"Conjunctival inflammation in dupilumab-treated atopic dermatitis comprises a multicellular infiltrate with elevated T1\/T17 cytokines: a case series study","volume":"76","author":"Bakker","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2022.09.005_bib100","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1097\/01.ico.0000178741.14212.53","article-title":"Atopic ocular surface disease: implications on tear function and ocular surface mucins","volume":"24","author":"Dogru","year":"2005","journal-title":"Cornea"},{"key":"10.1016\/j.alit.2022.09.005_bib101","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.exer.2013.08.013","article-title":"T\u00a0helper cytokines in dry eye disease","volume":"117","author":"Pflugfelder","year":"2013","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.alit.2022.09.005_bib102","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1046\/j.1365-2222.2000.00699.x","article-title":"Tear levels of interferon-gamma, interleukin (IL) -2, IL-4 and IL-5 in patients with vernal keratoconjunctivitis, atopic keratoconjunctivitis and allergic conjunctivitis","volume":"30","author":"Uchio","year":"2000","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.alit.2022.09.005_bib103","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jmb.2016.12.005","article-title":"Structural characterisation reveals mechanism of IL-13-neutralising monoclonal antibody tralokinumab as inhibition of binding to IL-13Ralpha1 and IL-13Ralpha2","volume":"429","author":"Popovic","year":"2017","journal-title":"J\u00a0Mol Biol"},{"key":"10.1016\/j.alit.2022.09.005_bib104","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.anai.2020.12.004","article-title":"Health-related quality of life with tralokinumab in moderate-to-severe atopic dermatitis: a phase 2b randomized study","volume":"126","author":"Silverberg","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.alit.2022.09.005_bib105","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/bjd.19573","article-title":"Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial","volume":"184","author":"Silverberg","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.alit.2022.09.005_bib106","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjd.19574","article-title":"Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)","volume":"184","author":"Wollenberg","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.alit.2022.09.005_bib107","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/bjd.20810","article-title":"Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: results from five tralokinumab clinical trials","volume":"186","author":"Wollenberg","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.alit.2022.09.005_bib108","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.jmb.2013.01.024","article-title":"Structural basis of signaling blockade by anti-IL-13 antibody Lebrikizumab","volume":"425","author":"Ultsch","year":"2013","journal-title":"J\u00a0Mol Biol"},{"key":"10.1016\/j.alit.2022.09.005_bib109","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1111\/cea.13731","article-title":"A\u00a0randomized, placebo-controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER)","volume":"50","author":"Austin","year":"2020","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.alit.2022.09.005_bib110","doi-asserted-by":"crossref","first-page":"1902442","DOI":"10.1183\/13993003.02442-2019","article-title":"Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosis","volume":"57","author":"Maher","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.alit.2022.09.005_bib111","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2018.01.017","article-title":"Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: a randomized, placebo-controlled phase II trial (TREBLE)","volume":"78","author":"Simpson","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.alit.2022.09.005_bib112","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jamadermatol.2020.0079","article-title":"Efficacy and safety of lebrikizumab, a high-affinity Interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial","volume":"156","author":"Guttman-Yassky","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.alit.2022.09.005_bib113","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/cea.14112","article-title":"Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: a systematic review and meta-analysis","volume":"52","author":"Charles","year":"2022","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.alit.2022.09.005_bib114","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/all.15056","article-title":"From DREAM to REALITI-A and beyond: mepolizumab for the treatment of eosinophil-driven diseases","volume":"77","author":"Pavord","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2022.09.005_bib115","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1080\/14712598.2019.1610382","article-title":"An evaluation of mepolizumab for the treatment of severe asthma","volume":"19","author":"Morjaria","year":"2019","journal-title":"Expet Opin Biol Ther"},{"key":"10.1016\/j.alit.2022.09.005_bib116","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1080\/17476348.2020.1739526","article-title":"Benralizumab: an updated treatment of eosinophilic asthma","volume":"14","author":"Cushen","year":"2020","journal-title":"Expet Rev Respir Med"},{"key":"10.1016\/j.alit.2022.09.005_bib117","doi-asserted-by":"crossref","first-page":"84","DOI":"10.18176\/jiaci.0385","article-title":"A\u00a0new approach for the treatment of severe eosinophilic asthma","volume":"29","author":"Davila Gonzalez","year":"2019","journal-title":"J\u00a0Investig Allergol Clin Immunol"},{"key":"10.1016\/j.alit.2022.09.005_bib118","first-page":"593","article-title":"Effects of eosinophil granule proteins on human corneal epithelial cell viability and morphology","volume":"38","author":"Trocme","year":"1997","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.alit.2022.09.005_bib119","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/S0002-9394(14)71463-1","article-title":"Eosinophil granule major basic protein deposition in corneal ulcers associated with vernal keratoconjunctivitis","volume":"115","author":"Trocme","year":"1993","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.alit.2022.09.005_bib120","doi-asserted-by":"crossref","first-page":"eaax2945","DOI":"10.1126\/scitranslmed.aax2945","article-title":"Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis","volume":"11","author":"Chen","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.alit.2022.09.005_bib121","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJMoa1917006","article-title":"Trial of nemolizumab and topical agents for atopic dermatitis with pruritus","volume":"383","author":"Kabashima","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.alit.2022.09.005_bib122","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jdermsci.2020.06.005","article-title":"Safety, tolerability and efficacy of repeated intravenous infusions of KHK4083, a fully human anti-OX40 monoclonal antibody, in Japanese patients with moderate to severe atopic dermatitis","volume":"99","author":"Nakagawa","year":"2020","journal-title":"J\u00a0Dermatol Sci"},{"key":"10.1016\/j.alit.2022.09.005_bib123","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.jaip.2021.02.003","article-title":"Emerging systemic therapeutic biologics and small molecules for atopic dermatitis: How to decide which treatment is right for your patients","volume":"9","author":"Ahn","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2022.09.005_bib124","first-page":"493","article-title":"[Allergic conjunctival diseases current status and near future treatment]","volume":"126","author":"Ebihara","year":"2021","journal-title":"Nippon Ganka Gakkai Zasshi"},{"key":"10.1016\/j.alit.2022.09.005_bib125","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/jdv.17981","article-title":"Dupilumab ocular side effects in patients with atopic dermatitis: a systematic review","volume":"36","author":"Neagu","year":"2022","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.alit.2022.09.005_bib126","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jtos.2020.05.008","article-title":"Ocular surface disease associated with dupilumab treatment for atopic diseases","volume":"19","author":"Utine","year":"2021","journal-title":"Ocul Surf"},{"key":"10.1016\/j.alit.2022.09.005_bib127","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.survophthal.2022.02.002","article-title":"Dupilumab-associated ocular manifestations: a review of clinical presentations and management","volume":"67","author":"Wu","year":"2022","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.alit.2022.09.005_bib128","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/bjd.16156","volume":"178","author":"de Bruin-Weller","year":"2018","journal-title":"Br J Dermatol"}],"container-title":["Allergology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1323893022001204?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1323893022001204?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:12:49Z","timestamp":1761156769000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1323893022001204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":128,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S1323893022001204"],"URL":"https:\/\/doi.org\/10.1016\/j.alit.2022.09.005","relation":{},"ISSN":["1323-8930"],"issn-type":[{"value":"1323-8930","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biologics for allergy: therapeutic potential for ocular allergic diseases and adverse effects on the eye","name":"articletitle","label":"Article Title"},{"value":"Allergology International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.alit.2022.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Japanese Society of Allergology. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}